R. Tonkens

Phase 1 b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

S. Steinhubl, R. Becker, Mauricio G. Cohen, 2008 .

Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

R. Becker, S. Zelenkofske, Mauricio G. Cohen, 2010 .

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

R. Becker, S. Zelenkofske, Mauricio G. Cohen, 2010, Circulation.

Interventional Cardiology First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

R. Becker, S. Zelenkofske, Mauricio G. Cohen, 2010 .

A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor

R. Becker, J. Alexander, R. Harrington, 2008, Journal of thrombosis and haemostasis : JTH.

Hand held programmable computers in emergency and critical care.

R. Tonkens, J. C. Brill, 1979, JACEP.

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

S. Steinhubl, R. Becker, Mauricio G. Cohen, 2008, Circulation.

An overview of the drug development process.

Ross Tonkens, R. Tonkens, 2005, Physician executive.